Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

• Key Intrahepatic cholangiocarcinoma pipeline therapies in various stages of development include Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.

Weill Cornell Medicine researchers have discovered that PD-1—a molecule best known for putting the brakes on immune ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Immutep is continuing the AIPAC-003 trial, which enrolled 71 metastatic hormone receptor positive (HR+), HER2-negative/low or ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose ...

Recent developments in the biliary tumor drug landscape have substantially expanded treatment options. In May 2024, AstraZeneca initiated Phase III clinical trials for Rilvegostomig, a promising ...

SUZHOU, China, July 29, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation ...

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options.